Schedule 2A, paragraph 9

Energetic materials as follows and mixtures thereof, except where the material is incorporated in a medical product— ammonium picrate (CAS 131-74-8); black powder; hexanitrodiphenylamine (CAS 131-73-7); difluoroamine (CAS 10405-27-3); nitrostarch (CAS 9056-38-6); tetranitronaphthalene; trinitroanisole; trinitronaphthalene; trinitroxylene; N-pyrrolidinone; 1-methyl-2-pyrrolidinone (CAS 872-50-4); dioctylmaleate (CAS 142-16-5); ethylhexylacrylate (CAS 103-11-7); triethylaluminium (TEA) (CAS 97-93-8), trimethylaluminium (TMA) (CAS 75-24-1), and other pyrophoric metal alkyls and aryls of lithium, sodium, magnesium, zinc or boron; nitroglycerin (or glyceroltrinitrate, trinitroglycerine) (NG) (CAS 55-63-0); Ethylenediaminedinitrate (EDDN) (CAS 20829-66-7); lead azide (CAS 13424-46-9), normal lead styphnate (CAS 15245-44-0) and basic lead styphnate (CAS 12403-82-6), and primary explosives or priming compositions containing azides or azide complexes; diethyldiphenylurea (CAS 85-98-3); dimethyldiphenylurea (CAS 611-92-7); methylethyldiphenyl urea; N,N-diphenylurea (unsymmetrical diphenylurea) (CAS 603-54-3); methyl-N,N-diphenylurea (methyl unsymmetrical diphenylurea) (CAS 13114-72-2); ethyl-N,N-diphenylurea (ethyl unsymmetrical diphenylurea) (CAS 64544-71-4); 4-Nitrodiphenylamine (4-NDPA)(CAS 836-30-6); 2,2-dinitropropanol (CAS 918-52-5). Note: For the purpose of this entry, “medical product” means (1) a pharmaceutical formulation designed for human administration in the treatment of medical conditions, and (2) prepackaged for distribution as a clinical or medical product.

← 8 · All articles · 10 →

Source: legislation.gov.uk · retrieved 2026-08-30